Revenue
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Chemours Co (CC)
Price$15.30Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.81B | $5.78B | $6.08B | $6.83B | $6.34B | $4.97B | $5.53B | $6.64B | $6.18B | $5.40B | $5.72B | $6.43B | $6.86B |
| Gross profit | $902.0M | $1.14B | $1.30B | $1.62B | $1.38B | $1.07B | $1.06B | $1.97B | $1.75B | $1.10B | $955.0M | $1.36B | $1.46B |
| Gross margin | 15.53% | 19.75% | 21.42% | 23.66% | 21.77% | 21.47% | 19.24% | 29.69% | 28.22% | 20.43% | 16.70% | 21.14% | 21.34% |
| Research & development | $108.0M | $109.0M | $108.0M | $118.0M | $107.0M | $93.0M | $80.0M | $82.0M | $81.0M | $81.0M | $97.0M | $143.0M | $164.0M |
| Operating expenses | $966.0M | $823.0M | $1.55B | $844.0M | $705.0M | $700.0M | $715.0M | $788.0M | $764.0M | $1.20B | $1.09B | $849.0M | $934.0M |
| Operating income | −$28.0M | $421.0M | −$123.0M | $786.0M | — | — | — | — | — | — | $4.63B | $5.58B | $5.92B |
| Operating margin | −0.48% | 7.28% | −2.02% | 11.51% | — | — | — | — | — | — | 80.99% | 86.80% | 86.38% |
| EBITDA | $332.0M | $661.0M | $199.0M | $1.20B | — | — | — | — | — | — | $4.90B | $5.84B | $6.19B |
| EBITDA margin | 5.72% | 11.43% | 3.27% | 17.49% | — | — | — | — | — | — | 85.66% | 90.80% | 90.19% |
| Net income | −$386.0M | $69.0M | −$253.0M | $578.0M | $608.0M | $219.0M | −$52.0M | $995.0M | $746.0M | $7.0M | −$90.0M | $400.0M | $423.0M |
| Net profit margin | −6.65% | 1.19% | −4.16% | 8.46% | 9.58% | 4.41% | −0.94% | 14.99% | 12.07% | 0.13% | −1.57% | 6.22% | 6.17% |
| Basic EPSper basic share | -$2.57 | $0.46 | -$1.70 | $3.72 | $3.69 | $1.33 | -$0.32 | $5.62 | $4.04 | $0.04 | -$0.50 | $2.21 | $2.34 |
| Diluted EPSper diluted share | -$2.57 | $0.46 | -$1.70 | $3.65 | $3.60 | $1.32 | -$0.32 | $5.45 | $3.91 | $0.04 | -$0.50 | $2.21 | $2.34 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 8, 2025Form 4 | Dignam DenisePresident & CEO | BuyCommon Stock | 4.1K | $12.06 | $49.1K | 191.5K |
| Jun 3, 2025Form 4 | Gumpel DamianSee Remarks | BuyCommon Stock | 7.8K | $9.95 | $77.8K | 131.7K |
| Jun 2, 2025Form 4 | Gumpel DamianSee Remarks | BuyCommon Stock | 13.4K | $9.22 | $123.5K | 123.9K |
| May 19, 2025Form 4 | HOSTETTER SHANEChief Financial Officer | BuyCommon Stock | 4.5K | $11.28 | $50.2K | 59.7K |
| Nov 7, 2024Form 4 | Scarborough AlveniaSVP Corp Communications & CBO | SellCommon Stock | 7.5K | $20.64 | $154.8K | 16.6K |
Community posts
Chemours, DuPont and Corteva agree to a $455 million PFAS settlement
Chemours ($CC), DuPont ($DD) and Corteva ($CTVA) reached an agreement to resolve PFAS-related claims brought by North Carolina and 11 local government entities. The settlement provides for $455 million in nominal payments over 15 years. Che ...